hydroxychloroquine has been researched along with DDD MPGNII in 4 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The patient received induction therapy with steroids, cyclophosphamide and hydroxychloroquine followed by rapid clinical improvement and remission of proteinuria." | 3.96 | A case report of hypocomplementemic urticarial vasculitis presenting with membranoproliferative glomerulonephritis. ( Boletis, JN; Liapis, G; Marinaki, S; Skalioti, C; Vallianou, K, 2020) |
| "The evolving pandemic of Coronavirus Disease 2019 has posed a substantial health risk worldwide." | 1.56 | A Patient with Cryoglobulinemic Membranoproliferative GN (MPGN) Who Survived COVID-19 Disease: Case Presentation and Current Data of COVID-19 Infection in Dialysis and Transplanted Patients in Greece. ( Argyraki, A; Boletis, I; Grigorakos, K; Lourida, P; Marinaki, S; Skalioti, C; Tsiakas, S, 2020) |
| "Mixed Connective Tissue Disorder with Castleman's Disease is a rare association; the patient presenting with varied and interesting manifestations." | 1.36 | Mixed connective tissue disorder and Castleman's disease. ( Boorugu, HK; Chrispal, A; Thomas, EM; Vasuki, Z, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marinaki, S | 2 |
| Tsiakas, S | 1 |
| Skalioti, C | 2 |
| Lourida, P | 1 |
| Argyraki, A | 1 |
| Grigorakos, K | 1 |
| Boletis, I | 1 |
| Vallianou, K | 1 |
| Liapis, G | 1 |
| Boletis, JN | 1 |
| Bojic, M | 1 |
| Kozakowski, N | 1 |
| Bécède, M | 1 |
| Kerschbaumer, A | 1 |
| Bobacz, K | 1 |
| Chrispal, A | 1 |
| Vasuki, Z | 1 |
| Thomas, EM | 1 |
| Boorugu, HK | 1 |
4 other studies available for hydroxychloroquine and DDD MPGNII
| Article | Year |
|---|---|
A Patient with Cryoglobulinemic Membranoproliferative GN (MPGN) Who Survived COVID-19 Disease: Case Presentation and Current Data of COVID-19 Infection in Dialysis and Transplanted Patients in Greece.
Topics: Anti-Bacterial Agents; Azithromycin; Betacoronavirus; Ceftriaxone; Coronavirus Infections; COVID-19; | 2020 |
A case report of hypocomplementemic urticarial vasculitis presenting with membranoproliferative glomerulonephritis.
Topics: Aged; Antirheumatic Agents; Arthritis; Chronic Urticaria; Complement System Proteins; Cyclophosphami | 2020 |
The Case | Myeloid bodies in the kidney biopsy of a patient with systemic lupus erythematosus.
Topics: Adult; Biopsy; Cyclophosphamide; Female; Glomerulonephritis, Membranoproliferative; Humans; Hydroxyc | 2017 |
Mixed connective tissue disorder and Castleman's disease.
Topics: Adolescent; Azathioprine; Biopsy; Castleman Disease; Female; Glomerulonephritis, Membranoproliferati | 2010 |